Arsanis, Inc. is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. The Company’s pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus. Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with a wholly owned subsidiary that is primarily focused on discovery research in Vienna, Austria (Arsanis Biosciences GmbH).
Helmut-Qualtinger-Gasse 2
1030 Vienna
Vienna
Contact:
Telephone: +43 (1) 79901-17
Email: office@arsanis.com
Website